Immune escape by Epstein-Barr virus associated malignancies

Christian Münz; Ann Moormann

doi:10.1016/j.semcancer.2008.10.002

Immune escape by Epstein-Barr virus associated malignancies

Christian Münz, Ann Moormann

Research output: Contribution to journal › Review article › peer-review

91 Scopus citations

Abstract

Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.

Original language	English
Pages (from-to)	381-387
Number of pages	7
Journal	Seminars in Cancer Biology
Volume	18
Issue number	6
DOIs	https://doi.org/10.1016/j.semcancer.2008.10.002
State	Published - Dec 2008
Externally published	Yes

Keywords

Burkitt's lymphoma
HIV
Hodgkin's lymphoma
Malaria
Nasopharyngeal carcinoma
T cells

Access to Document

10.1016/j.semcancer.2008.10.002

Cite this

@article{558e14e2e61e45d1b4feed3a65048ff3,

title = "Immune escape by Epstein-Barr virus associated malignancies",

abstract = "Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.",

keywords = "Burkitt's lymphoma, HIV, Hodgkin's lymphoma, Malaria, Nasopharyngeal carcinoma, T cells",

author = "Christian M{\"u}nz and Ann Moormann",

note = "Funding Information: Our research is supported by the Arnold and Mabel Beckman Foundation, the Alexandrine and Alexander Sinsheimer Foundation, the Burroughs Wellcome Fund, the Dana Foundation's Neuroimmunology program, the Starr Foundation, the National Cancer Institute (R01CA108609 and R01CA101741), the National Institute of Allergy and Infectious diseases (RFP-NIH-NIAID-DAIDS-BAA-06-19), the Foundation for the National Institutes of Health (Grand Challenges in Global Health) (to C.M.), and an Institutional Clinical and Translational Science Award (to the Rockefeller University Hospital). A.M. is supported by NIH K08-AI51565 and NIAID-AI43906. ",

year = "2008",

month = dec,

doi = "10.1016/j.semcancer.2008.10.002",

language = "English",

volume = "18",

pages = "381--387",

journal = "Seminars in Cancer Biology",

issn = "1044-579X",

publisher = "Academic Press",

number = "6",

}

TY - JOUR

T1 - Immune escape by Epstein-Barr virus associated malignancies

AU - Münz, Christian

AU - Moormann, Ann

N1 - Funding Information: Our research is supported by the Arnold and Mabel Beckman Foundation, the Alexandrine and Alexander Sinsheimer Foundation, the Burroughs Wellcome Fund, the Dana Foundation's Neuroimmunology program, the Starr Foundation, the National Cancer Institute (R01CA108609 and R01CA101741), the National Institute of Allergy and Infectious diseases (RFP-NIH-NIAID-DAIDS-BAA-06-19), the Foundation for the National Institutes of Health (Grand Challenges in Global Health) (to C.M.), and an Institutional Clinical and Translational Science Award (to the Rockefeller University Hospital). A.M. is supported by NIH K08-AI51565 and NIAID-AI43906.

PY - 2008/12

Y1 - 2008/12

N2 - Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.

AB - Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.

KW - Burkitt's lymphoma

KW - HIV

KW - Hodgkin's lymphoma

KW - Malaria

KW - Nasopharyngeal carcinoma

KW - T cells

UR - https://www.scopus.com/pages/publications/56949101640

U2 - 10.1016/j.semcancer.2008.10.002

DO - 10.1016/j.semcancer.2008.10.002

M3 - Review article

C2 - 18996483

AN - SCOPUS:56949101640

SN - 1044-579X

VL - 18

SP - 381

EP - 387

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

IS - 6

ER -

Immune escape by Epstein-Barr virus associated malignancies

Abstract

Keywords

Access to Document

Fingerprint

Cite this